RLS-0071 + ruxolitinib

**RLS-0071 + ruxolitinib** is an investigational combination therapy being studied for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in hospitalized patients. RLS-0071 is an investigational peptide drug developed with a dual-targeting mechanism that modulates both complement and innate inflammatory pathways, aiming to suppress inflammation and tissue damage. Ruxolitinib is an FDA-approved small molecule inhibitor that selectively targets Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), thereby blocking cytokine-mediated signaling critical to the pathogenic immune response in aGVHD. The combination is currently under Phase 2 evaluation to establish safety, dosing, and efficacy[1][3][5][7].

Other names

RLS-0071RLS0071RLS 0071ruxolitinib phosphate